Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subject: BFA

Physician-Scientist Steven Quay: Forensic examination of Wuhan Institute of Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen more lethal than Ebola

SEATTLE, July 26, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay and a group of international scientists have published a pre-print, available here, entitled, "CONTAMINATION OR VACCINE RESEARCH? RNA Sequencing data of early COVID-19 patient samples show abnormal presence of vectorized H7N9 hemagglutinin segment." In the paper, a forensic examination of the sequencing data from five COVID-19 bronchial lavage patient specimens reveals that the laboratory at the Wuhan Institute of Virology (WIV) was contaminated with a wide range of viruses, including Nipah virus genes in a cloning vector. Nipah is a BSL-4 pathogen with a lethality of 50% to 92%. A video summary of the paper can be found here. 

The highlights of the paper are:

"It was surprising to find a menagerie of deadly viruses, strange pathogens, and even honeysuckle, plant genes in patient specimens sequenced at the WIV in December 2019, especially since this patient sequencing data has been publicly available to the entire scientific community inside of the US NIH GenBank database since February 2020," stated Dr. Steven Quay, MD, PhD. "The apparent widespread contamination of the laboratory at the very time the pandemic was just beginning is of course worrisome. But more important is getting answers to these questions: Why do these patient specimens contain an unreported influenza vaccine? What was the purpose of creating an undisclosed, apparently infectious clone of the deadly Nipah virus? Is this Nipah research part of another gain-of-function research project at the Wuhan Institute of Virology?"

About the Nipah Virus
Nipah virus, scientific name Nipah henipavirus, is a bat-borne virus that causes an infection in humans and other animals, with a high mortality rate. Numerous disease outbreaks caused by Nipah virus have occurred in South and Southeast Asia. Symptoms from infection vary from none to fever, cough, headache, shortness of breath, and confusion. This may worsen into a coma over a day or two, and 50% to 92% of those infected die. Complications can include inflammation of the brain and seizures following recovery. At this time there is no specific treatment for Nipah virus infection nor is there a vaccine..

About Steven Quay, M.D., Ph.D.
Dr. Steven Quay has over 360 published contributions to medicine and has been cited over 10,500 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have been prescribed to over 80 million people. He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus. He is the CEO of Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and infectious diseases.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 220,000 times.  His scientific manuscript entitled, "A Bayesian analysis concludes beyond a reasonable doubt that SARS-CoV-2 is not a natural zoonosis but instead is laboratory derived," has been viewed over 175,000-times. For more information, visit www.DrQuay.com

Public Relations Contact: 
Dunn Pellier Media| t: 323.481.2307
11620 Wilshire Blvd., 9th Floor, Los Angeles, CA 90025

SOURCE Dr. Steven Quay

These press releases may also interest you

at 20:35
Lobe Sciences Ltd. ("Lobe" or the "Company") is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion ("mTBI") and post-traumatic stress disorder ("PTSD"),...

at 20:00
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, released...

at 19:29
The Honourable Carolyn Bennett, Minister of Crown-Indigenous Relations, the Honourable Patty Hajdu, Minister of Health, the Honourable Marc Miller, Minister of Indigenous Services and the Honourable Daniel Vandal, Minister of Northern Affairs, issued...

at 18:42
AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTAtm (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor...

at 18:20
Element Blue, a leader in intelligent automation specializing in the healthcare sector, has retained its status as a UiPath Gold Partner. In 2017 Element Blue became a Gold Partner with UiPath ? the leading enterprise Robotic Process Automation (RPA)...

at 18:19
StemExpress announces it will be providing tours of its groundbreaking pandemic response Mobile Laboratory, Thursday, September 30th at its Rockville, Maryland location. Guests and press are invited to schedule a private tour to learn about this...

News published on 26 july 2021 at 09:00 and distributed by: